Skip to main content
Home / News / Major Release of Certara GlobalSubmit™ Software Enhances the Regulatory Submission Process

Major Release of Certara GlobalSubmit™ Software Enhances the Regulatory Submission Process

Radnor, PA – November 25, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that a new version of its GlobalSubmit regulatory submissions software is generally available. The latest version supports the FDA’s new version 4.0 submission standard, improving the submission process while increasing harmonization across health authorities’ requirements.

Certara’s GlobalSubmit is used by regulatory affairs, medical writing teams, and scientists to efficiently publish, validate, and review Electronic Common Technical Document (eCTD) submissions of new drugs and biologics to health authorities. The latest version of Global Submit was developed with input from the FDA, current customers, and Certara’s large team of regulatory experts. GlobalSubmit has been used across the industry for over 15 years and has processed over 1.5 million regulatory submissions.

“Certara solutions support customers throughout the entire drug development lifecycle,” said William Feehery, CEO at Certara. “The latest version of GlobalSubmit, especially when combined with CoAuthor™, Certara’s generative AI-enabled regulatory writing platform, helps clients avoid risks and unnecessary delays during the submission process.”

The latest version of GlobalSubmit includes updated granularity, context groups, and re-used files. In addition to the GlobalSubmit software, Certara’s expert regulatory operations team provides the assurance needed to navigate the new standard seamlessly. The FDA is the second regulatory authority to begin accepting eCTD 4.0 submissions.

For more information on GlobalSubmit and Certara regulatory operations solutions, visit https://www.certara.com/globalsubmit-ectd-submission-software/

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Certara Contact: 
Sheila Rocchio 
sheila.rocchio@certara.com  

Media Contact:
Alyssa Horowitz 
certara@pancomm.com